Risteys · H7_GLAUCINOTH

Endpoint definition steps	FinnGen
Phenotype data	520210
1. Apply sex-specific rule None	520210
2. Check conditions None	520210
3. Check pre-conditions, main-only, mode, registry filters Registry filters: Hospital discharge: ICD-10 — H42* Hospital discharge: ICD-9 — 3654A Cause of death: ICD-10 — H42* Cause of death: ICD-9 — 3654A 2 out of 7 registries used, show all original rules.	15
4. Check minimum number of events None	15
5. Include endpoints None	15
6. Filter based on genotype QC (FinnGen only)	15

Summary Statistics

↥

-FinRegistry-

Key figures

	All	Female	Male
Number of individuals
Whole population	230	114	113
Only index persons	166	86	80
Unadjusted period prevalence (%)
Whole population	0.00	0.00	0.00
Only index persons	0.00	0.00	0.00
Median age at first event (years)
Whole population	49.52	58.00	40.92
Only index persons	39.59	48.45	30.07

-FinnGen-

Key figures

	All	Female	Male
Number of individuals	15	-	11
Unadjusted period prevalence (%)	0.00	-	0.00
Median age at first event (years)	32.43	-	33.02

-FinRegistry-

Age distribution of first events

-FinnGen-

Age distribution of first events

-FinRegistry-

Year distribution of first events

-FinnGen-

Year distribution of first events

-FinRegistry-

Cumulative Incidence Function

No data

-FinnGen-

Cumulative Incidence Function

Not a core endpoint, no data to show.

CodeWAS (R11)

↥

CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.

This is a new tool, please reach out using the contact form for feedback and improvement ideas.

First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log₁₀(p-value) ≥ 6.

No data available

LabWAS

↥

(ID) Name

N Cases

N Controls

-log₁₀(p)

cases

controls

unit

cases

controls

-log₁₀(p)

N cases

N controls

(3003458) Phosphate [Moles/volume] in Serum or Plasma

4.44

1.67

33.8

4.7

mmol/l

1.2

1.0

—

(3011397) Hemoglobin [Presence] in Urine by Test strip

3.64

1.55

9.3

2.9

—

(46236098) ABO and Rh group [Type] in Blood by Confirmatory method

2.76

1.04

4.5

1.8

—

(3026008) Bacteria identified in Urine by Culture

2.65

1.01

3.8

2.5

—

(3033658) Prothrombin time (PT) actual/Normal

2.54

0.98

8.7

5.1

89.8

87.7

—

(3018418) pH of Serum or Plasma

2.56

0.91

25.3

4.7

—

7.4

—

(3048689) Calprotectin [Mass/mass] in Stool

0.00

0.88

0.0

3.1

—

414.9

—

(3051714) Fibrin D-dimer FEU [Mass/volume] in Platelet poor plasma

2.48

0.82

2.4

1.7

mg/l

1.7

1.1

—

(3001079) Blood group antibody screen [Presence] in Serum or Plasma

2.14

0.77

5.4

3.5

—

(3016431) Calcium.ionized [Moles/volume] adjusted to pH 7.4 in Serum or Plasma

2.12

0.74

33.1

7.3

mmol/l

1.2

—

(3044889) 12 lead EKG panel

2.16

0.73

3.7

3.5

—

(40758558) Short blood count panel - Blood

2.26

0.70

7.3

8.2

—

(3002256) Pathology report gross observation

0.00

0.65

0.0

1.4

—

(3015736) pH of Urine

2.10

0.62

8.3

2.6

—

(3037522) Nuclear Ab [Titer] in Serum

0.00

0.44

0.0

1.5

—

288.0

—

(3021440) Promyelocytes/100 leukocytes in Blood

0.00

0.44

0.0

4.6

—

0.2

—

(3017181) Myelocytes/100 leukocytes in Blood

0.00

0.44

0.0

4.6

—

0.6

—

(21494755) Public health laboratory ask at order entry panel

0.00

0.44

0.0

1.5

—

(3025159) Blasts/100 leukocytes in Blood

0.00

0.44

0.0

4.6

—

1.6

—

(3003510) Neisseria gonorrhoeae DNA [Presence] in Urine by NAA with probe detection

0.00

0.43

0.0

2.6

—

(3024950) Chlamydia trachomatis DNA [Presence] in Urine by NAA with probe detection

0.00

0.43

0.0

2.9

—

(3022145) Colonoscopy Study observation

0.00

0.43

0.0

1.9

—

(3029287) Urinalysis microscopic panel [#/volume] - Urine by Automated count

1.60

0.41

9.5

2.9

—

(3013603) Prostate specific Ag [Mass/volume] in Serum or Plasma

1.60

0.41

7.2

3.7

ug/l

15.5

1.8

—

(3021601) Nitrite [Presence] in Urine by Test strip

1.74

0.41

11.7

4.9

—

0.0

—

(3009261) Glucose [Presence] in Urine by Test strip

1.69

0.40

8.4

3.6

—

0.0

—

(3035350) Ketones [Presence] in Urine by Test strip

1.55

0.38

8.4

3.5

—

0.0

—

(36304419) Bacteria [Presence] in Urine

1.58

0.28

5.6

2.8

—

(3009508) Creatinine [Moles/volume] in Urine

1.47

0.27

5.0

2.7

mmol/l

5.2

9.7

—

(3044640) Blood type and Crossmatch panel - Blood

1.42

0.26

6.0

1.9

—

(3021347) Calcium.ionized [Moles/volume] in Serum or Plasma

1.42

0.23

34.7

5.8

mmol/l

1.2

—

(3013707) Erythrocyte sedimentation rate by Westergren method

0.72

0.23

3.1

5.0

mm/h

21.1

10.8

—

(3000494) Fungus identified in Specimen by Culture

0.00

0.22

0.0

1.1

—

(3006093) Chlamydia trachomatis DNA [Presence] in Specimen by NAA with probe detection

0.00

0.22

0.0

1.7

—

(42868674) Cholesterol in HDL/Cholesterol.total [Molar ratio] in Serum or Plasma

0.00

0.22

0.0

4.1

—

26.3

—

(3032080) INR in Blood by Coagulation assay

1.20

0.11

4.4

6.0

—

1.1

—

(3008486) Thyroxine (T4) free [Moles/volume] in Serum or Plasma

1.24

0.10

3.9

3.3

pmol/l

14.5

14.9

—

(706163) SARS-CoV-2 (COVID-19) RNA [Presence] in Respiratory system specimen by NAA with probe detection

1.03

0.00

3.8

3.5

—

(3037467) Urinalysis macro (dipstick) panel - Urine

1.14

0.00

5.0

3.7

—

(3043238) Trisomy 21 risk [Likelihood] in Fetus

0.00

0.0

1.7

—

(40765161) Human bocavirus DNA [Presence] in Specimen by NAA with probe detection

0.00

0.0

1.8

—

(3019145) Choriogonadotropin.beta subunit free [Mass/volume] in Serum or Plasma

0.00

0.0

1.7

—

(3013139) Helicobacter pylori Ag [Presence] in Stool

0.00

0.0

1.0

—

(3025941) Bacteria identified in Stool by Culture

0.00

0.0

1.6

—

(3047352) Trisomy 18 risk [Likelihood] in Fetus

0.00

0.0

1.8

—

(1001926) Buprenorphine [Presence] in Urine by Screen method

0.00

0.0

1.2

—

(46235831) Pregnancy associated plasma protein A [Multiple of the median] adjusted in Serum or Plasma

0.00

0.0

1.8

—

(3027008) Opiates [Presence] in Urine

0.00

0.0

1.3

—

(3021584) Pregnancy associated plasma protein A [Units/volume] in Serum or Plasma

0.00

0.0

1.7

—

(3040853) Adenovirus DNA [Identifier] in Specimen by NAA with probe detection

0.00

0.0

1.7

—

(36032419) SARS-CoV-2 (COVID-19) Ag [Presence] in Upper respiratory specimen by Immunoassay

0.00

0.0

1.8

—

(3028300) Cannabinoids [Presence] in Urine

0.00

0.0

1.3

—

(3007566) Smooth muscle Ab [Titer] in Serum

0.00

0.0

1.6

—

(36033641) SARS-CoV-2 (COVID-19) Ag [Presence] in Upper respiratory specimen by Rapid immunoassay

0.00

0.0

2.2

—

(3003327) Ova and parasites identified in Stool by Light microscopy

0.00

0.0

1.3

—

(3016650) Hepatitis A virus Ab [Presence] in Serum

0.00

0.0

1.0

—

(3008714) Choriogonadotropin [Multiple of the median] adjusted in Serum or Plasma

0.00

0.0

1.8

—

(3050129) First trimester maternal screen panel - Serum or Plasma

0.00

0.0

1.5

—

(3004716) Salmonella sp identified in Stool by Organism specific culture

0.00

0.0

1.3

—

(40763531) Fetal Nuchal fold [Multiple of the median] Thickness adjusted for maternal weight

0.00

0.0

1.8

—

(3011288) Drugs identified in Urine by Screen method

0.00

0.0

1.0

—

(3034770) Mitochondria Ab [Titer] in Serum

0.00

0.0

1.6

—

(3027944) Amphetamines [Presence] in Urine

0.00

0.0

1.3

—

(40761536) Microorganisms panel - Urine sediment

0.00

0.0

4.6

—

(3042596) Human coronavirus RNA [Presence] in Specimen by NAA with probe detection

0.00

0.0

1.8

—

(3011371) Neisseria gonorrhoeae DNA [Presence] in Specimen by NAA with probe detection

0.00

0.0

2.0

—

(3013115) Eosinophils [#/volume] in Blood

0.95

0.00

10.8

6.5

e9/l

0.2

—

(3020961) Endomysium IgA Ab [Titer] in Serum

0.00

0.0

1.0

—

(3022914) Cancer Ag 19-9 [Units/volume] in Serum or Plasma

0.00

0.0

4.8

—

38.6

—

(3049207) Fetal Trisomy 21 risk [Likelihood] Based on maternal age

0.00

0.0

1.8

—

(3042194) Human metapneumovirus RNA [Presence] in Specimen by NAA with probe detection

0.00

0.0

1.7

—

(3034780) Angiotensin converting enzyme [Enzymatic activity/volume] in Serum or Plasma

0.00

0.0

1.8

—

49.3

—

(3016879) Cocaine [Presence] in Urine

0.00

0.0

1.2

—

(3000764) Benzodiazepines [Presence] in Urine

0.00

0.0

1.3

—

(42529201) Cancer Ag 19-9 [Units/volume] in Serum or Plasma by Immunoassay

0.00

0.0

1.4

—

12.3

—

(3016251) Hemoglobin.gastrointestinal [Presence] in Stool

0.00

0.0

1.7

—

(3005033) Fetal Nuchal fold Thickness US

0.00

0.0

1.8

—

(3008898) HLA-B27 [Presence]

0.00

0.0

1.0

—

(3005322) IgE [Units/volume] in Serum or Plasma

0.00

0.0

1.2

—

16.2

—

(3030692) Respiratory virus DNA+RNA [Identifier] in Specimen by NAA with probe detection

0.00

0.0

1.8

—

Mortality – FinRegistry

↥

Association

Association between endpoint H7_GLAUCINOTH and mortality.

Females

No data

Males

No data

Mortality risk

Mortality risk for people of age

years, who have H7_GLAUCINOTH.

N-year risk	Females	Males
1	No data	No data
5	No data	No data
10	No data	No data
15	No data	No data
20	No data	No data

Relationships between endpoints

↥

Index endpoint: H7_GLAUCINOTH – Glaucoma in diseases classified elsewhere

GWS hits: -

Endpoint

Case Overlap

Survival Analysis

Genetic Correlations

Genetic Signals

N (Jaccard index)

HR [CI]

Extremity

rg [CI]

Extremity

Hits

Coloc Hits

FinRegistry

FinnGen

FinRegistry

FinnGen

Loading data

NAME	H7_GLAUCINOTH
CONTROL_EXCLUDE	H7_GLAUCOMA
CONTROL_PRECONDITIONS
CONTROL_CONDITIONS
SEX
INCLUDE
PRE_CONDITIONS
CONDITIONS
OUTPAT_ICD
OUTPAT_OPER
HD_MAINONLY
HD_ICD_10_ATC
HD_ICD_10	H42
HD_ICD_9	3654A
HD_ICD_8	$!$	The FinnGen clinical team has checked and no code can be used for this rule.
HD_ICD_10_EXCL
HD_ICD_9_EXCL
HD_ICD_8_EXCL
COD_MAINONLY
COD_ICD_10	H42
COD_ICD_9	3654A
COD_ICD_8	$!$	The FinnGen clinical team has checked and no code can be used for this rule.
COD_ICD_10_EXCL
COD_ICD_9_EXCL
COD_ICD_8_EXCL
OPER_NOM
OPER_HL
OPER_HP1
OPER_HP2
KELA_REIMB
KELA_REIMB_ICD
KELA_ATC_NEEDOTHER
KELA_ATC
KELA_VNRO_NEEDOTHER
KELA_VNRO
CANC_TOPO
CANC_TOPO_EXCL
CANC_MORPH
CANC_MORPH_EXCL
CANC_BEHAV

Glaucoma in diseases classified elsewhere

Endpoint definition

Endpoint definition steps

FinnGen

Phenotype data

1. Apply sex-specific rule

2. Check conditions

3. Check pre-conditions, main-only, mode, registry filters

4. Check minimum number of events

5. Include endpoints

6. Filter based on genotype QC (FinnGen only)

Similar endpoints

Case counts by codes

Summary Statistics

-FinRegistry-

Key figures

-FinnGen-

Key figures

-FinRegistry-

Age distribution of first events

-FinnGen-

Age distribution of first events

-FinRegistry-

Year distribution of first events

-FinnGen-

Year distribution of first events

-FinRegistry-

Cumulative Incidence Function

-FinnGen-

Cumulative Incidence Function

CodeWAS (R11)

LabWAS

Mortality – FinRegistry

Association

Females

Males

Mortality risk

Relationships between endpoints